Vidar Wendel-Hansen
Technik-/Wissenschafts-/F&E-Leiter bei TOLERANZIA AB
Aktive Positionen von Vidar Wendel-Hansen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TOLERANZIA AB | Technik-/Wissenschafts-/F&E-Leiter | 17.01.2018 | - |
QUIAPEG PHARMACEUTICALS HOLDING AB | Technik-/Wissenschafts-/F&E-Leiter | - | - |
VWH & Co. AB | Direktor/Vorstandsmitglied | - | - |
Castello Di Vaglio Serra AB | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Vidar Wendel-Hansen
Ehemalige bekannte Positionen von Vidar Wendel-Hansen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ASARINA PHARMA AB | Direktor/Vorstandsmitglied | 01.01.2019 | 05.05.2020 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Corporate Officer/Principal | 01.01.2005 | 24.06.2010 |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Vorstandsvorsitzender | 20.06.2018 | - |
Novartis Sverige AB
Novartis Sverige AB Pharmaceuticals: MajorHealth Technology Novartis Sverige AB trades pharmaceutical products. It offers products for the treatment of ADHD, multiple sclerosis, urticaria, allergic asthma, psoriasis, chronic obstructive pulmonary disorder, migraine, blood diseases, eye disorder, and other diseases. The company is headquartered in Kista, Sweden. | Direktor/Vorstandsmitglied | - | - |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2011 | - |
░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ | |
░░░░░░░░ ░░ | ░░░░░░░ | - | - |
░░░░░░ ░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | ░░░░░░░░░░ |
Ausbildung von Vidar Wendel-Hansen
Karolinska Institutet | Doctorate Degree |
Statistik
International
Schweden | 12 |
Vereinigte Staaten | 2 |
Norwegen | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 4 |
Director/Board Member | 4 |
Corporate Officer/Principal | 3 |
Sektoral
Health Technology | 11 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
ASARINA PHARMA AB | Health Technology |
TOLERANZIA AB | Health Technology |
QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
Private Unternehmen | 8 |
---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
Arexis AB
Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Health Technology |
Quiatech AB
Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Health Technology |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Novartis Sverige AB
Novartis Sverige AB Pharmaceuticals: MajorHealth Technology Novartis Sverige AB trades pharmaceutical products. It offers products for the treatment of ADHD, multiple sclerosis, urticaria, allergic asthma, psoriasis, chronic obstructive pulmonary disorder, migraine, blood diseases, eye disorder, and other diseases. The company is headquartered in Kista, Sweden. | Health Technology |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Health Technology |
VWH & Co. AB | |
Castello Di Vaglio Serra AB |
- Börse
- Insiders
- Vidar Wendel-Hansen
- Erfahrung